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Abstract
Studies into the impact of vaccination against the varicella zoster virus (VZV) have increasingly focused on
herpes zoster (HZ), which is believed to be increasing temporally in vaccinated populations with decreasing
infection pressure. This idea can be traced back to Hope-Simpson’s hypothesis, in which a person’s immune
status determines the likelihood that he/she will develop HZ. Immunity decreases over time, and can be
boosted by contact with a person experiencing varicella (exogenous boosting) or by a reactivation attempt
of the virus (endogenous boosting). Here we use transmission models to estimate age-specific rates of
reactivation and immune boosting, exogenous as well as endogenous, using zoster incidence data from the
Netherlands (2002-2011, n = 7, 026). The boosting and reactivation rates are estimated with splines,
enabling these quantities to be optimally informed by the data. The analyses show that models with high
levels of exogenous boosting and estimated or zero endogenous boosting, constant rate of loss of immunity,
and reactivation rate increasing with age (to more than 5% per year in the elderly) give the best fit to
the data. Estimates of the rates of immune boosting and reactivation are strongly correlated. This has
important implications as these parameters determine the fraction of the population with waned immunity.
We conclude that independent evidence on rates of immune boosting and reactivation in persons with waned
immunity are needed to robustly predict the impact of varicella vaccination on the incidence of HZ.
Highlights
• We estimate age-specific rates of VZV reactivation and immune boosting using HZ incidence data
• We find high rates of exogenous and lower rates of endogenous immune boosting, while reactivation
rates increase strongly with age
• A substantial part of the adult population is expected to be unavailable for reactivation leading to HZ
• High estimated rates of exogenous immune boosting lend credibility to the idea that HZ incidence
depends on VZV circulation
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Introduction
Varicella zoster virus (VZV) is a herpes virus causing a disease known as chickenpox or varicella. After
resolving of the systemic primary infection, the virus remains latently present in the host. The virus can
reactivate later in life, resulting in a disease known as herpes zoster (HZ) or shingles. Dating back to the work
of Hope-Simpson [12], it has been hypothesized that boosting of the immune system of a latently infected
person by contact with a person experiencing chickenpox could lower the probability of HZ developing at
some point later in life [3, 10, 20, 19, 29]. If true, such exogenous immune boosting could have profound
implications for vaccination programs aimed at reducing chickenpox, as these are expected to reduce virus
transmission and exogenous immune boosting. Over the years this has become a popular hypothesis to
explain and predict the dynamics of HZ in unvaccinated and vaccinated populations, and an important
reserve for countries to introduce VZV vaccination [2, 3, 10, 25].
While earlier studies focused exclusively on the implications of exogenous boosting [1, 3, 10, 11, 21, 25, 31],
Hope-Simpson’s original hypothesis states that both exogenous and endogenous boosting, by reactivation
attempts of the virus that are successfully countered by the immune system of the host, contribute to the
maintenance of immunity. Although data are scarce, some studies indeed show subclinical reactivation in
specific populations, most likely in response to stress [5, 14, 16, 24, 33]. It is therefore of particular interest
to evaluate the joint ability of endogenous and exogenous boosting to explain the available HZ incidence
data, and to obtain insight in the relative strength of endogenous versus exogenous immune boosting. Here
we build on earlier studies [1, 3, 10, 11, 25, 21, 31] to obtain estimates of key parameters determining the
dynamics of VZV in unvaccinated and vaccinated populations. Specifically, we use long-term HZ incidence
data from the Netherlands (2002-2011, n = 7, 026 cases [31]) to estimate age-specific rates of immune
boosting, loss of immunity, and reactivation in a population without VZV vaccination. Our approach
extends earlier analyses by i) including the possibility of endogenous next to exogenous immune boosting,
and ii) allowing the age-specific rates of reactivation and immune boosting to have flexible shapes, using
natural cubic splines. In this manner, the shapes and values of the rate functions are optimally informed
by the data, in contrast to previous studies that have made restrictive assumptions from the onset (e.g.,
[10, 31]).
The analyses reveal that rates of loss of immunity are high (0.048 − 0.10 per year), that reactivation
rates are low up to 40 years, increase strongly to 0.03− 0.10 per year at old age, and that the fraction of the
population with waned immunity that is prone to HZ decreases from 45%− 55% at age 25 to 10%− 40% at
age 80, and depends sensitively on whether or not endogenous boosting is taken into account. Our analyses
show that exogenous boosting is stronger than endogenous immune boosting in children and adults with
young children, and that it is conceivable that endogenous boosting exceeds exogenous boosting in other
age strata. We discuss the implications for vaccination programs aiming to reduce chickenpox, and possible
future avenues to obtain further quantitative information on the magnitude of the Hope-Simpson effect.
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Figure 1: Overview of varicella zoster virus (VZV) seroprevalence (i.e. fraction of the population infected) (left-hand panel)




The prevalence of VZV by age is based on Dutch serological data, derived from the second cross-
sectional serosurveillance study (PIENTER2), conducted among people aged 0-79 years in the Netherlands
in 2006/2007 [30]. The seroprevalence of VZV in the PIENTER2 study is quantitatively very similar to the
seroprevalence in the earlier PIENTER1 study (conducted in 1995/1996), indicating little change of the age
at infection with VZV over the period 1996-2006 [7, 32]. To avoid the interference of maternal antibodies
we only include the 6,251 samples of participants aged 6 months or older. The VZV seroprevalence data
provide the basis for estimation of the basic reproduction number of VZV using the so-called social contact
hypothesis [31]. Here we use the earlier estimates of the force of infection as input for estimation of the
rates of reactivation and immune boosting. The data and earlier model fit are shown in Figure 1, and can
be downloaded in the data supplement of an earlier publication [31].
Herpes zoster incidence
Sentinel data on the incidence of general practitioner (GP) consultations due to HZ by age in the period
2002-2011 (based on 7,026 cases) are provided by NIVEL, the Netherlands Institute for Health Services
Research [31]. The majority of HZ patients consult their GP because it is a painful condition. Because HZ
complaints are highly specific and accompanied by typical lesions, with a positive predictive value of clinical
judgment of 90.8% (95%CI: 87.3% − 94.3%), we expect that misclassification of the diagnosis by the GP
is rare [22]. Hence, we use the sentinel GP data as a proxy for the total incidence of HZ in the catchment
population. The HZ data can be downloaded in the data supplement of an earlier publication [31], and
shows no increase or decrease of incidence over time, and no relative increase or decrease in any age group
in the study period. The HZ data are the main source of information on which estimates of the rates of










Figure 2: Schematic of the model under the short-disease approximation. S(a) denotes the age-specific prevalence of uninfected
persons, V (a) the age-specific prevalence of latently infected persons with sufficient immunity to prevent reactivation, W (a)
the prevalence of latently infected persons with waned immunity, and R(a) the prevalence of persons who have experienced HZ.
The force of infection and rate of exogenous immune boosting are given by λ(a) and zλ(a), and the rates of loss of immunity,
endogenous immune boosting, and reactivation are given by η(a), γ(a), and ρ(a).
Model structure and analysis
The mathematical model to describe progression to HZ is based on earlier studies [10, 25, 31]. We
extend these models by i) including endogenous next to exogenous immune boosting, as in Hope-Simpson’s
original hypothesis [12], and ii) allowing for the rates of reactivation and immune boosting to be relatively
unconstrained, using natural cubic splines.
The population is assumed to be in demographic equilibrium, and infectious contacts (i.e. contacts suffi-
cient for transmission) between persons of different ages are made according to the social contact hypothesis.
This implies that the probability of an infectious contact is proportional to observed contact patterns in the
Netherlands [17, 31]. We also assume, as in earlier studies and backed by empirical evidence, that primary
varicella is infectious and that infectiousness of HZ is negligible [10, 28, 31]. Next, we assume in our main
analyses that reactivation can occur at most once during a lifetime [12, 23]. We have also considered an
extension of the main model in which multiple reactivations are possible, and obtained similar results (Ap-
pendix E). For this reason, we focus here on the model with at most one reactivation in a person’s lifetime
(Figure 2).
Further, the duration of varicella and HZ episodes (weeks to months) are short compared with the human
lifespan (decades), and we may therefore use the short-disease approximation in which the varicella and HZ
states are not explicitly modeled [9]. Finally, as in earlier studies [10, 25] but contrasting with others [15],
we model the distribution of persons over classes by age with a fixed contact structure, with demographic
composition as in the Netherlands during collection of the contact data.
Figure 2 shows a schematic of the model, and Equations (1)-(2) give a mathematical description. Indi-
viduals are born susceptible to VZV infection (in the S class). From the S compartment individuals are
infected at an age-specific rate λ(a) (the force of infection), after which they enter the V compartment
(latently infected with immunity to reactivation). Immunity to reactivation is lost at a rate η(a), and gained
at rates zλ(a) and γ(a) by exogenous and endogenous boosting respectively. Reactivation from the latently
infected compartment with waned immunity W occurs at a rate ρ(a), and individuals who have experienced
HZ after reactivation enter the R compartment.
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= λ(a)S(a)− η(a)V (a) + (zλ(a) + γ(a))W (a),
dW (a)
da
= η(a)V (a)− (zλ(a) + γ(a) + ρ(a))W (a),
dR(a)
da
= ρ(a)W (a) ,
(1)




c(a, s)λ(s)S(s)ds , (2)
and initial conditions S(0) = 1, V (0) = 0, W (0) = 0, and R(0) = 0. In the above, M = 100 (yr) is
the maximum age, c(a, s) is the contact rate between individuals of age s and those of age a, and q is
the proportionality parameter that has been estimated from seroprevalence data. Specifically, with proper
scaling of the contact function the proportionality parameter q can be equated with the basic reproduction
number R0. Throughout we take R̂0 = 8.7 (95%CI: 8.1− 9.3), as estimated using seroprevalence data [31].
Notice that this implies that in the Netherlands infection of infants and children occurs at a relatively young
age [18, 32]. Notice furthermore that the above implicitly implies that we do not use the explicit Equation (2)
in the estimation procedure, but rather insert the estimate of force of infection λ̂(a) in Equation (1) (Figure 1)
as obtained earlier [31]. In this manner, all other estimates of transition rates are fully compatible with the
serological data (Figure 1), at the (slight) cost that the force of infection may not be optimally informed by
the HZ incidence data [31].
Discretization
Statistical inference of transition rates is based on a discretized approximation of the expanded state
space [9, 10, 31]. First, we extend the state space by keeping track not only of whether individuals are
latently infected with or without immunity to reactivation (i.e. in compartments V and W ), but also by
counting the number of times that individuals have passed through the V and W compartments. Hence,
Vi and Wi refer to individuals who are in the V and W compartments for the i-th time. We can then
solve Equation (1) recursively for all Vi and Wi (i = 1, 2, . . .) in terms of the force of infection λ(a). Next
we approximate the system by assuming that individuals can only cycle through the Vi and Wi states for
a certain number of times. Backed by preliminary analyses we take this number to be 5, as the error so
introduced remains small when compared to results with higher maximal number of cycles (not shown).
Finally, we discretize the solutions for Vi and Wi to be able to tie the modeled to the observed incidence of
HZ. Since the HZ incidence data are available in age groups of 1 year, we also take age groups of 1 year in
the discretization. Details are given in Appendix A.
Natural cubic splines
Flexible estimation of the transition rates η(a), γ(a), and ρ(a) is ensured by using natural cubic splines
[6]. A cubic spline is a smooth function that is constructed from cubic polynomial pieces that are joined
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at certain knots, and that have continuous first and second derivatives [6]. For cubic splines the number of
polynomial basis functions (pieces) is m = n+ 3, where n is the number of age intervals. For simplicity, we
assume throughout that the intervals are of the same length.





where βT = (β1, ...,βm) are the coefficients of the basis functions that need to be estimated. Based on the
above, the discretized age-specific rates fT = (f(a1), ...f(a100)) are given by
f = Bβ,
where B = (bij) = Bj(ai). We evaluate the performance of models for a range of values for n using Akaike
information criterion (AIC) and Bayesian information criterion (BIC) to select the optimal number of age
intervals [4]. Appendix B shows results for n = 4, . . . , 7. The analyses suggest that n = 6 is optimal (i.e.
knots at xi =
100i
6 years, with i = 0, 1, ..., 6), and we will use this value throughout. Hence, m = 9 and B is
a 100× 9 matrix.
Estimation and model selection
Estimates of the parameters are obtained by maximization of the likelihood of the HZ incidence. As the
number of cases is small compared to the number of person-years, both with regard to the total number of
cases and total number of person-years (7, 026 and 2, 049, 362) and the numbers per age group, we use a
Poisson likelihood with parameter ρiWiNi, where ρiWi is the expected (modeled) incidence rate of HZ in
age group i, and Ni is the number of person-years. Confidence intervals of parameters (η, ρ, γ, and z) are
calculated by direct resampling of the data. Here, 200 resampled data sets are generated assuming that the
number of HZ cases in each of the age-classes follows a Binomial distribution with binomial totals Ni and
parameter Ii/Ni), where Ni and Ii are the reported number of individuals and reported number of cases
in age-class i, respectively. Throughout we use age classes of one year, so that with the exception of the
youngest age classes (< 4 years) each age class contains more than 50 cases. For each of the resampled data
sets the parameters are re-estimated, and percentile bootstrap confidence intervals are calculated. Model
selection is based on AIC and BIC differences [4]. All analyses are performed using R 3.2 [26].
Scenarios
We consider a suite of scenarios to estimate the rate of loss of immunity to reactivation (η(a)), the
rate of endogenous immune boosting (γ(a)), the relative susceptibility of latently infected individuals to
exogenous immune boosting (z), and the reactivation rate (ρ(a)). The scenarios differ by whether the rates
are assumed constant or estimated with age-dependent splines. In the baseline scenario (Scenario 1) all
rates are estimated with splines. In Scenarios 2-4 one rate parameter is assumed constant at a time, in
Scenarios 5-7 two rates are assumed constant, and in Scenario 8 all three rates are constant. Finally, based
on preliminary analyses we also include a Scenario (Scenario 6*) in which the exogenous reactivation rate is
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Scenario Constant rates Label log(Lmax) ∆AIC ∆BIC df
1 - -347.5 16.0 60.2 28
2 γ -348.0 0.8 24.2 20
3 ρ -352.7 10.4 33.7 20
4 η -351.9 8.7 32.1 20
5 γ, ρ -360.2 9.2 11.8 12
6 γ, η Model with endogenous boosting -354.8 -1.6 0.98 12
6* γ ≡ 0, η Model without endogenous boosting -356.6 0 0 11
7 ρ, η -383.7 56.3 58.9 12
8 all rates -1363.7 2000.3 1982.1 4
Table 1: Overview of model fits. A suite of simplifications of the baseline model (Scenario 1) are considered in which one or more
of the parameters are constant instead of being modeled with splines. Shown are the maximized log-likelihood (log(Lmax)),
the associated AIC and BIC differences with the best-fitting model Scenario 6∗ in the main text, and the degrees of freedom
(df). The best-fitting model does not include endogenous immune boosting (γ ≡ 0), and has a constant rate of loss of immunity
(η̂ = 0.076 (yr−1)). See Table 2 for an overview of parameter estimates.
assumed to be zero (γ ≡ 0). All these scenarios include exogenous boosting. To validate this choice, we also
consider a similar suite of scenarios that do not include exogenous boosting (see Appendix C). As expected,
these models give a worse fit to the data.
Results
Table 1 gives an overview of fits of the different Scenarios based on AIC and BIC differences. Scenarios
with all rates assumed constant (Scenario 8) or with constant rates of reactivation and loss of immunity
(Scenario 7) do not perform well (∆AIC and ∆BIC with the best fitting model are well over 50 in both
cases). Better fits are obtained with models in which all parameters are estimated with splines (Scenario 1),
in which one of the rate parameters is assumed constant (Scenarios 2-4), or in which both the rate of
endogenous boosting (γ) and the reactivation rate (ρ) are constant (Scenario 5). Overall, the best-fitting
models have a constant or zero rate of endogenous immune boosting, constant rate of loss of immunity, and
age-specific rate of reactivation. We henceforth focus on these two models, which we will label the model
with (Scenarios 6) and without (Scenarios 6*) endogenous boosting.
Parameter estimates of the best-fitting models with and without endogenous boosting are given in Table
2 and Figure 3. Both scenarios produce good and similar fits to the HZ incidence data (Figure 3). Waning
of immunity occurs on a time scale that varies from 20 years (η̂ = 0.048 per year (95%CI : 0.033− 0.068))
in the model with endogenous boosting to 13 years (η̂ = 0.076 per year (95%CI : 0.063 − 0.087)) in the
model without endogenous boosting. Further, while the endogenous reactivation rate is 0 in the model
without endogenous boosting, it is estimated at γ̂ = 0.093 per year (95%CI : 0.069 − 0.11) in the model
with endogenous boosting. Susceptibility of latently infected individuals relative to the susceptibility of
uninfected persons per infectious contact is estimated to be approximately 1 (ẑ = 1 (95%CI : 0.0.998−1) in
the model with endogenous boosting and ẑ = 0.987 (95%CI : 0.986−0.990) in the model without endogenous
boosting), this indicates that an infectious contact that would lead to infection of an uninfected person is
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Scenario Parameter
η (year−1) (95%CI) γ (year−1) (95%CI) z (95%CI)
6 0.048 (0.033− 0.068) 0.093 (0.069− 0.114) 1 (0.998− 1)
6∗ 0.076 (0.063− 0.087) - 0.987 (0.986− 0.990)
Table 2: Parameter estimates of the scenarios with and without endogenous immune boosting (cf. Table 1). Shown are
maximum likelihood estimates with 95% confidence bounds for parameters that are assumed constant. See Figure 2 for
parameters estimated with splines.
also sufficient to lead to immune boosting. As a consequence, exogenous immune boosting almost equals the
force of infection (Figure 1), and in children and in the age group of adults with young children (≈ 30− 40
years) exogenous immune boosting exceeds endogenous boosting (if present). In older adults (> 40 years)
and older children and young adults (< 30 years) who have a low estimated force of infection, exogenous
immune boosting is expected to be less prominent, and endogenous boosting exceeds exogenous boosting in
the model with immune boosting, perhaps with exception of grandparents with young grandchildren (≈ 65
years).
Estimated reactivation rates are age-dependent in both scenarios with high statistical support, increasing
with age from, say, 40 years onwards. Specifically, estimates are approximately 0.10 per year in elderly in
the model with endogenous immune boosting and over 0.02 per year in the model without endogenous
immune boosting (Figure 3). Interestingly, the reactivation rates are substantially higher in the model with
endogenous boosting than in the model without endogenous boosting from the age of 60 years onwards,
while the estimated fraction that is available for reactivation (Ŵ (a)) is substantially higher in the model
without endogenous immune boosting (Figure 3). Hence, both scenarios make different interpretations on
the fraction of the population that is available for reactivation in older adults and elderly. Hence, while the
models provide similar fits to the HZ incidence data, there are significant underlying differences with regard
to the rates of endogenous immune boosting, reactivation, and fraction of the population that is available
for reactivation.
Although it is expected that the majority of cases of HZ is reported to a GP [22], some degree of under-
ascertainment is conceivable. Additionally, even though HZ symptoms are highly specific, it is possible that
some reported cases of HZ may have been misdiagnosed. To investigate the robustness of the above results
to under- and over-ascertainment, we have have reanalyzed the data assuming 10% under-ascertainment
and 10% over-ascertainment. The results of the analyses are laid down in Appendix D (see Table 5 and
Figure 5 for details) and show that the results with either under- or over-ascertainment are quantitatively
close to the results obtained in Tables 1-2 and Figure 3.
Discussion
Our analyses provide support for the hypothesis of Hope-Simpson [12] that immune boosting affects
the incidence of HZ. Our results add to earlier studies [1, 10, 11, 25, 31] by showing that immune boost-
ing is a potent force in a model that includes both endogenous and exogenous boosting, and that allows
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Figure 3: HZ incidence data and overview of the best-fitting models (left-hand panels: with endogenous immune boosting,
right-hand panels: without endogenous immune boosting). Shown are the observed and predicted incidence of HZ in both
scenarios (top panels; dots: data; lines: prediction), the fraction of the population with waned immunity (W (a)) (middle
panels), and the estimated reactivation rates (ρ(a))(bottom panels). Lines correspond to maximum likelihood estimates and
shaded areas to bootstrapped 95% confidence ranges. Also shown are the reactivation rates as estimated for Italy, Finland, the
UK, and Germany in more restrictive analyses [3, 25].
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the reactivation rate to take flexible shapes. Our quantitative estimations further show that in most age
groups the rate of exogenous immune boosting is substantially higher than the rate of endogenous immune
boosting, but also underline that even low estimated rates of endogenous immune boosting significantly
affect the distribution of latently infected individuals with and without waned immunity. More generally,
the distribution of latently infected individuals with and without immunity to reactivation is shaped by an
intricate interplay between the age-specific rates at which immunity is lost and gained (see also [1, 11]),
and even small rates of endogenous boosting could affect this distribution significantly. The main reason
is that there is no direct information underpinning which part of the adult population is latently infected
with and without waned immunity. The implication is that not all individuals who are latently infected may
be available for developing HZ, but that the exact fraction cannot be estimated with precision. Hence, for
public health considerable uncertainty remains about the potential effectiveness of HZ vaccination of elderly.
Waning of immunity and, to a lesser extent, immune boosting are well documented, and have been
included in an agent-based transmission model to anticipate the impact of varicella vaccination of HZ
incidence [21]. In this model, immunity is a continuous quantity, and each individual is equipped with
his/her own level of (cellular) immunity. This contrasts with our model in which immunity to reactivation
is either complete (compartment V ) or completely absent (compartment W ). From a biological perspective,
the earlier model [21] is biologically more plausible, while our current model is simpler and more amenable
to formal statistical inference. In both models, much of the remaining variation and uncertainty derives from
the fact that there is very little data to pinpoint exactly which fraction of the adult population is available
for reactivation.
A number of assumptions need scrutiny. First, we have assumed, as in earlier studies (e.g., [10, 25]),
that the force of infection is known. Here we have taken the force of infection as estimated from Dutch
seroprevalence data [31]. Ideally, all parameters of interest would be estimated in one go, taking into account
both the seroprevalence and HZ incidence data. This is, however, computationally demanding. Further,
it has been argued that the basic reproduction number and force of infection are strongly identified by
serological data, thereby diminishing the need to include all data in one synthesizing analysis [31]. Earlier
studies have taken a similar approach in which the force of infection is estimated first, and then in a second
step the transition rates are estimated from HZ incidence [10, 25, 31].
Second, our analyses are based on the arbitrary assumption that the splines have five interior knots.
This seems to produce reasonably flexible shapes of the reactivation rate without grossly overparameterizing
the model. It should be noted, however, that whether or not models with constant or flexible rates of
boosting, loss of immunity, and reactivation are preferred by information criteria such as AIC or BIC
depends not only on the data but also on the number of additional parameters (and hence the number
of knots). A computationally more involved alternative could for instance make use of penalized splines
in which a penalty is used to avoid excessive fluctuations of the rate functions [8]. This, however, would
also necessitate estimation of the effective number of parameters, and cannot address the question whether
it is likely or not that certain parameters are constant, as is invariably assumed in modeling studies. In a
sensitivity analysis we have decreased and increased the number of knots and obtained quantitatively similar
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results, showing that our results do not depend sensitively on the degree of freedom of the rate functions
(Appendix B).
Figure 3 shows the reactivation rates as estimated using our model from Dutch HZ incidence data together
with estimates of the reactivation rates as estimated earlier using HZ incidence data from Germany, Finland,
Italy, and the UK [3, 25]. Interestingly, our estimates are close to earlier estimates by Brisson and colleagues
up to the age of 60 [3]. In older age groups our estimates of the reactivation rates are substantially higher
in the scenario with endogenous immune boosting. This can be attributed to the fact that in this scenario
more older persons have functional immunity due to endogenous boosting, and higher reactivation rates
are required to explain the HZ incidence data. Also interesting is the finding in our study and the earlier
studies by Brisson and colleagues and Poletti and colleagues that the estimated reactivation rate decreases
in childhood until the age of 23 years. In the earlier studies one could have argued that this is a consequence
of the relative inflexibility of the function describing the reactivation rate. This explanation, however, does
not hold in our analyses, and suggests that the high estimated reactivation rates in children may reflect a
true biological phenomenon. A reasonable explanation might be that for some reason the immune system
of children has not (yet) acquired full control of the virus.
Our results have potential implications for large-scale varicella and combined varicella and zoster vacci-
nation programs. Our two main scenarios (Figure 3) make different explanations on how the observed zoster
cases are produced. In the model with endogenous boosting the fraction of persons with waned immunity is
small while the reactivation rate is high, while in the model without endogenous boosting the fraction with
waned immunity is higher but the reactivation rate is lower. Indiscriminate zoster vaccination is expected
to prevent similar number of cases of HZ in both cases. However, this expectation may not hold anymore
if large-scale varicella vaccination is added to the mix. In this case, the force of infection is expected to be
reduced to a similar extent in both scenarios as estimates of the exogenous boosting parameter z are very
close in both scenarios (Table 2). As a result, the impact of exogenous boosting is expected to be reduced
to a similar extent after the introduction of varicella vaccination. However, immune boosting is still a factor
in the model with endogenous boosting (cf. Table 2). As a consequence, one would expect that persons
that are exogenously boosted in the absence of varicella vaccination could still be boosted endogenously in
the presence of varicella vaccination. This could potentially lead to a less dramatic transient increase in the
incidence of HZ after the introduction of varicella vaccination than predicted earlier [3, 10, 11, 13, 27, 31].
The downside would be that the added value of zoster vaccination would also be diminished. Of course, in
an ideal scenario it would be possible to target zoster vaccination specifically to those persons with waned
immunity who are at risk of developing zoster.
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Appendix A. Model Solution and Discretization
We base our estimation procedures on the ODEs specified by Equations (1)-(2). In the analyses we
use earlier estimates of the force of infection λ(a) [31], and obtain maximum likelihood estimates of other
parameters using the discretized solution of Equation (1). Specifically, the population is split into J = 100
age classes of 1 year.
As a first step we expand the state space by keeping track of the number of times that an individual has
been in the V and W compartments [10]. Hence, Vi(a) represents the fraction of the population of age a
who are in the V compartment for the i-th time (i = 1, 2, . . .). See Figure 4 for a schematic of the model











= (zλ(a) + γ(a))Wi−1(a)− η(a)Vi(a)
dWi(a)
da
= η(a)Vi(a)− (zλ(a) + γ(a) + ρ(a))Wi(a) ,
(3)
with i = 2, 3, . . . and appropriate initial conditions. In the above, the (total) fractions V (a) and W (a) in
the latently infected compartments are given by infinite sums V (a) =
∑∞
i=1 Vi(a) and W (a) =
∑∞
i=1Wi(a).
Reasonable approximations for these sums can be obtained by assuming that there is a finite but sufficiently
large number of times n that an individual can pass through the V and W compartments during its lifetime.








with n ∈ Z+. In practice, these approximations work well already for small n [10]. Here we take n = 5,
which gives results that quantitatively close to those obtained when taking n = 10 (results not shown).
The ODEs with expanded state space can be solved recursively, starting with S(a), V1(a), and W1(a).













































Figure 4: Schematic of the model with expanded state space (cf. Figure 2).
with i ≥ 2 and S(0) = 1 the only non-zero initial condition. It follows that V (a) and W (a) can be
approximated by




W (a) ≈W1(a) +
n∑
i=2
















Next, we discretize Equation (4) as follows. If the limits of the J = 100 age classes are defined by the
vector a = (0, 1, ..., J), then the jth class contains all persons with age in the interval [a[j], a[j+1]), where a[j]
denotes the j-th element of a. Using this notation, the force of infection λ(a) and the rates η(a), ρ(a), and
γ(a) are replaced by their discretized counterpart λj , ηj , ρj , and γj , and Vi and Wi (i,= 1, ..., n, j = 1, ..., J)






















































































Appendix B. Optimal Number of Age Intervals
To determine the optimal number of age intervals we have re-analyzed the data using the scenarios of
Table 1, while varying the number of age intervals from n = 4 to n = 7 (5 to 8 knots). The results are
shown in Table 3 below.
Number of age intervals Scenario Rates assumed constant log(Lmax) ∆AIC ∆BIC df
4
1 - -355.4 19.7 48.2 22
2 γ -357.2 11.3 24.3 16
3 ρ -359.5 15.9 28.8 16
4 η -356.8 10.6 23.5 16
5 γ, ρ -370.3 25.5 22.9 10
6 γ, η -362.2 13.3 15.9 10
6* γ ≡ 0, η -382.3 51.5 51.5 9
7 ρ, η -413.9 112.7 110.0 10
5
1 - -354.9 24.7 61.1 25
2 γ -353.7 8.4 26.6 18
3 ρ -357.9 16.7 35.0 18
4 η -355.5 12.0 30.2 18
5 γ, ρ -370.9 28.8 28.7 11
6 γ, η -369.0 26.9 29.4 11
6* γ ≡ 0, η -380.0 46.9 46.9 10
7 ρ, η -395.4 77.8 77.7 11
6
1 - -347.5 16.0 60.2 28
2 γ -348.0 0.8 24.2 20
3 ρ -352.7 10.4 33.7 20
4 η -351.9 8.7 32.1 20
5 γ, ρ -360.2 9.2 11.8 12
6 γ, η -354.8 -1.6 0.98 12
6* γ ≡ 0, η -356.6 0 0 11
7 ρ, η -383.7 56.3 58.9 12
7
1 - -352.9 32.8 84.9 31
2 γ -346.9 2.7 31.3 22
3 ρ -353.8 16.5 45.1 22
4 η -353.3 15.6 44.2 22
5 γ, ρ -356.0 2.8 8.0 13
6 γ, η -358.7 8.3 13.5 13
6* γ ≡ 0, η -403.5 95.8 98.4 12
7 ρ, η -373.4 37.7 42.8 13
Table 3: Overview of analyses with varying number of age intervals. See main text for details.
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Appendix C. A Model Without Exogenous Boosting
In the main text we focus on model scenarios with exogenous immune boosting, as put forward by
Hope-Simpson [12]. Here we provide a sensitivity analysis showing that model scenarios without exogenous
boosting have low empirical support compared to scenarios with exogenous boosting. In Table 4 we present
log(Lmax), and AIC and BIC differences of these models with the best-fitting model Scenario 6* in the main
text.
Scenario Rates assumed constant log(Lmax) ∆AIC ∆BIC df
1 - -360.5 40.0 81.7 27
2 γ -351.9 6.76 27.6 19
3 ρ -358.9 20.6 41.5 19
4 η -358.8 20.4 41.2 19
5 γ, ρ -373.8 34.5 34.5 11
6 γ, η -366.7 20.2 20.2 11
6∗ γ ≡ 0, η -379.5 44.0 41.4 10
7 ρ, η -387.5 61.8 61.8 11
8 all rates -2996.8 5266.5 5248.3 3
Table 4: Overview of fits of model scenarios without exogenous boosting (cf. Table 1). A suite of simplifications of the
baseline model (Scenario 1) are considered in which one or more of the parameters are constant instead of being modeled with
splines. Shown are the maximized log-likelihood (log(Lmax)), the associated AIC and BIC differences with the best-fitting
model Scenario 6∗ in the main text, and the degrees of freedom (df).
Appendix D. Under- and Over-Ascertainment
To further investigate the robustness of our estimates, we analyze two additional scenarios assuming
10% under-ascertainment and 10% over-ascertainment. Specifically, we increase or decrease the observed
number of HZ infections by 10%, and re-estimate the parameters. Table 5 and Figure 5 show results of the
best-fitting Scenarios 6 and 6∗.
Scenario Assumption Parameter
η (year−1) γ (year−1) z
6 10% over-ascertainment 0.048 0.11 1
6 10% under-ascertainment 0.053 0.080 1
6* 10% over-ascertainment 0.076 - 0.981
6* 10% under-ascertainment 0.078 - 0.987
Table 5: Parameter estimates of model scenarios with under- or over-ascertainment and with or without endogenous immune
boosting (cf. Table 1). Shown are maximum likelihood estimates with 95% confidence bounds for parameters that are assumed
constant. See also Figure 5.
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Figure 5: Model fits in the presence of under- and over-ascertainment(left-hand panels: with endogenous immune boosting;
right-hand panels: without endogenous immune boosting). Shown are the observed and predicted incidence of HZ in both
scenarios (top panels), the fraction of the population with waned immunity (W (a)) (middle panels), and the estimated reac-
tivation rates (ρ(a))(bottom panels). Dashed lines correspond to maximum likelihood estimates presented in the main text
(Figure 3) for the scenarios. Continuous lines refer to maximum likelihood estimates assuming 10% under-ascertainment (blue)
and 10% over-ascertainment (green).
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Appendix E. A Model with Multiple Reactivations
The model in the main text assumes that only one reactivation can take place in a person’s life. Here
we investigate whether the results so obtained still hold in a model with multiple reactivations. The model
structure is shown in Figure 6. In order not to overcomplicate the model we assume that reactivation leads
to immune boosting, and that immunity wanes at an age-specific rate η(a) that does not depend on the
number of reactivation events that a person has already gone through. The results of the analyses are given
in Tables 6-7 and Figure 7 (cf. Tables 1-2 and Figure 3). Overall, these analyses give similar fits to the data
as analyses with models that do not include multiple reactivation (Table 7), and mainly differ with respect







Figure 6: Schematic of the model with multiple reactivations. S(a) denotes the age-specific prevalence of uninfected persons,
V (a) the age-specific prevalence of latently infected persons with sufficient immunity to prevent reactivation, and W (a) the
prevalence of latently infected persons with waned immunity. The force of infection and rate of exogenous immune boosting
are given by λ(a) and zλ(a), and the rates of loss of immunity, endogenous immune boosting, and reactivation are given by
η(a), γ(a), and ρ(a). The age-specific incidence of reactivation is given by ρ(a)W (a)






= λ(a)S(a)− η(a)V (a) + (zλ(a) + γ(a) + ρ(a))W (a),
dW (a)
da
= η(a)V (a)− (zλ(a) + γ(a) + ρ(a))W (a) .























































































η (year−1) (95%CI) γ (year−1) (95%CI) z (95%CI)
6 0.084 (0.073− 0.100) 0.10 (0.093− 0.13) 0.978 (0.977− 0.984)
6∗ 0.042 (0.025− 0.044) - 0.990 (0.989− 0.994)
Table 6: Parameter estimates of the scenarios with and without endogenous immune boosting and multiple reactions (cf.
Table 2). Shown are maximum likelihood estimates with 95% confidence bounds for parameters that are assumed constant.
Scenario Rates assumed constant log(Lmax) ∆AIC ∆BIC df
1 - -347.7 16.3 60.6 28
2 γ -353.1 11.1 34.5 20
3 ρ -352.7 10.4 33.8 20
4 η -351.2 7.4 30.8 20
5 γ, ρ -360.6 10.1 12.7 12
6 γ, η -354.8 -1.4 1.2 12
6∗ γ ≡ 0, η -356.6 0.2 0.2 11
7 ρ, η -383.0 54.9 57.5 12
8 all rates -1176.0 1626.0 1607.7 4
Table 7: Overview of fits of model scenarios with multiple reactivations (cf. Table 1). A suite of simplifications of the baseline
model (Scenario 1) are considered in which one or more of the parameters are constant instead of being modeled with splines.
Shown are the maximized log-likelihood (log(Lmax)), the associated AIC and BIC differences with the best-fitting model
Scenario 6∗ in the main text, and the degrees of freedom (df).
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Figure 7: HZ incidence data and overview of the best-fitting models (left-hand panels: with endogenous immune boosting,
right-hand panels: without endogenous immune boosting). Shown are the observed and predicted incidence of HZ in both
scenarios (top panels; dots: data; lines: prediction), the fraction of the population with waned immunity (W (a)) (middle
panels), and the estimated reactivation rates (ρ(a))(bottom panels). Lines correspond to maximum likelihood estimates and
shaded areas to bootstrapped 95% confidence ranges. Also shown are the corresponding estimates in the model without multiple
reactivation (Figure 3).
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